News Nicox glaucoma drug works, but not as well as hoped Nicox has had both good and bad news from a much-anticipated phase 3 trial of its glaucoma therapy candidate NCX 470.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
